Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Purdue Withdraws Palladone; FDA Evaluating Other Extended-Release Opiates

Executive Summary

FDA is evaluating the potential for an alcohol interaction with other sustained-release opiates following the withdrawal of Purdue Pharma's Palladone due to the potential for serious alcohol-related adverse events

You may also be interested in...



Opana Withdrawal Request Builds On US FDA Actions On Palladone, OxyContin

Earlier withdrawals of Purdue’s Palladone and original OxyContin create precedent for request that Endo’s Opana ER come off market due to risk of abuse; former chief counsel sees agency's move as ‘tip of the iceberg’ on opioid safety actions.

FDA Stays Positive On Rx Safety Info Sheets, But Drug Watch Still In Question

Drug information sheets published by FDA in 2005 demonstrate the agency's focus on important safety issues, Drug Safety Oversight Board Executive Director Susan Cummins said Jan. 23 at a Drug Information Association conference in Washington, D.C

FDA Stays Positive On Rx Safety Info Sheets, But Drug Watch Still In Question

Drug information sheets published by FDA in 2005 demonstrate the agency's focus on important safety issues, Drug Safety Oversight Board Executive Director Susan Cummins said Jan. 23 at a Drug Information Association conference in Washington, D.C

Related Content

Topics

UsernamePublicRestriction

Register

PS046098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel